【Abstract】 Domestic studies have shown that metastatic prostate cancer (mPC) has a prevalence of approximately 54% in patients with first-stage prostate cancer, and its five-year survival rate is two times lower than non-metastatic cancer. The resistance of metastatic prostate cancer for existing drugs has increased year by year, which makes it critical to optimize treatment options. The European Journal of Urology, the European Society of Radiation Oncology, the European Society of Urogenital Radiology and the International Association of Geriatric Oncology (EAU-ESTRO-ESUR-SI- OG) , based on major clinical and basic experiments, develop annual guidelines for the treatment of mPC to guide the clinical treatments and disease monitoring, which enjoys tremendous popularity. Therefore, in order to better promote diagnosis and treatment guidelines and standardize treatment of mPC, this article will interpret the treatment update, treatment detection and treatment timing of mPC in the 2019 EAU-EANM-ESTRO-ESUR-SIOG guide.